kidney cancer
-
MedCity Pivot Podcast: Season 3 Launches With A Conversation On the Potential Toxicity of Immunotherapy
Transformations in the Life Sciences is the focus of the second season of the MedCity Pivot Podcast. My personal journey as a caregiver of a cancer patient made me choose Dr. Sumanta Pal, co-director of the City of Hope’s Liver Cancer program as a guest after he co-authored an interesting study on immunotherapy that was published in the Lancet.
-
BMS and Nektar end cancer drug alliance after two more clinical trial failures
Bristol Myers Squibb and Nektar Therapeutics are ending a cancer drug research alliance after data showed the combination of their respective drugs failed clinical trials in kidney and bladder cancers. The disappointing results come one month after the drug combo failed a pivotal melanoma clinical trial.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Merck, Eisai drug combo nabs FDA nod as first-line kidney cancer therapy
FDA approval of a therapy that pairs drugs from Eisai and Merck allows the combination to become a first-line treatment for renal cell carcinoma. It’s the latest approval for the partners, which have been working together since 2018.
-
AVEO Oncology puts off seeking FDA approval for kidney cancer drug until 1Q20
The agency told the company it still had lingering reservations about the results of a Phase III trial that had been designed to allay agency concerns. Shares of the company fell 38 percent on the news.
-
Rosetta Genomics announces patent for gene expression signature to distinguish four types of kidney cancer
The ability to more accurately define the different types of cancer, it could lead to lowering costs for treatment and reducing complications.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
